Profound Medical says CAPTAIN trial shows TULSA preserves penile length vs robotic prostatectomy at 1 month

PUBT · 2d ago
Profound Medical says CAPTAIN trial shows TULSA preserves penile length vs robotic prostatectomy at 1 month
  • Profound Medical released new CAPTAIN randomized trial data comparing its TULSA Procedure with robotic prostate removal in intermediate-risk prostate cancer.
  • Results were presented earlier today at the Society of Robotic Surgery Annual Meeting.
  • TULSA showed better short-term preservation of penile length versus surgery, a quality-of-life outcome that can influence treatment choice.
  • The update follows previously disclosed trial results showing TULSA outperformed robotic surgery on erectile function and urinary continence at six months.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Profound Medical Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607241015PRIMZONEFULLFEED9767698) on July 24, 2026, and is solely responsible for the information contained therein.